[go: up one dir, main page]

WO2005044293A3 - Compositions able to prevent neurodegenerative processes and methods of assaying the same - Google Patents

Compositions able to prevent neurodegenerative processes and methods of assaying the same Download PDF

Info

Publication number
WO2005044293A3
WO2005044293A3 PCT/IT2004/000612 IT2004000612W WO2005044293A3 WO 2005044293 A3 WO2005044293 A3 WO 2005044293A3 IT 2004000612 W IT2004000612 W IT 2004000612W WO 2005044293 A3 WO2005044293 A3 WO 2005044293A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
assaying
same
prevent neurodegenerative
Prior art date
Application number
PCT/IT2004/000612
Other languages
French (fr)
Other versions
WO2005044293A2 (en
Inventor
Simona Capsoni
Antonio Cattaneo
Sonia Covaceuszach
Francesca Paoletti
Michela Visintin
Original Assignee
Lay Line Genomics Spa
Simona Capsoni
Antonio Cattaneo
Sonia Covaceuszach
Francesca Paoletti
Michela Visintin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITRM20030517 external-priority patent/ITRM20030517A1/en
Priority claimed from ITRM20040373 external-priority patent/ITRM20040373A1/en
Application filed by Lay Line Genomics Spa, Simona Capsoni, Antonio Cattaneo, Sonia Covaceuszach, Francesca Paoletti, Michela Visintin filed Critical Lay Line Genomics Spa
Priority to EP04799407A priority Critical patent/EP1682170A2/en
Publication of WO2005044293A2 publication Critical patent/WO2005044293A2/en
Publication of WO2005044293A3 publication Critical patent/WO2005044293A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to compositions able to prevent neurodegenerative events and methods to assay their activity. In particular, the invention relates to compositions comprising inhibitors of the proNGF (pro-Nerve Growth Factor) or of the p75 receptor and/or of its co-receptors, such as sortilin, and methods for assaying their activity.
PCT/IT2004/000612 2003-11-07 2004-11-08 Compositions able to prevent neurodegenerative processes and methods of assaying the same WO2005044293A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04799407A EP1682170A2 (en) 2003-11-07 2004-11-08 Compositions able to prevent neurodegenerative processes and methods of assaying the same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ITRM2003A000517 2003-11-07
ITRM20030517 ITRM20030517A1 (en) 2003-11-07 2003-11-07 COMPOSITIONS ABLE TO PREVENT NEURODEGENERATIVE EVENTS AND METHOD TO TEST ITS ACTIVITY.
ITRM2004A000373 2004-07-21
ITRM20040373 ITRM20040373A1 (en) 2004-07-21 2004-07-21 METHOD FOR IDENTIFYING A SELECTIVE PRONGF INHIBITOR AND SELECTED INHIBITORS WITH IT.

Publications (2)

Publication Number Publication Date
WO2005044293A2 WO2005044293A2 (en) 2005-05-19
WO2005044293A3 true WO2005044293A3 (en) 2005-06-16

Family

ID=34575792

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2004/000612 WO2005044293A2 (en) 2003-11-07 2004-11-08 Compositions able to prevent neurodegenerative processes and methods of assaying the same

Country Status (2)

Country Link
EP (1) EP1682170A2 (en)
WO (1) WO2005044293A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435523B2 (en) 2009-05-04 2013-05-07 Abbott Research B.V. Antibodies against nerve growth factor (NGF) with enhanced in vivo stability

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030601A1 (en) 2003-12-24 2005-06-25 Lay Line Genomics Spa METHOD FOR THE HUMANIZATION OF HUMANIZED ANTIBODIES AND ANTIBODIES WITH IT OBTAINED.
ITRM20050290A1 (en) 2005-06-07 2006-12-08 Lay Line Genomics Spa USE OF MOLECULES ABLE TO INHIBIT THE BOND BETWEEN NGF AND ITS TRKA RECEPTOR AS AN EXTENDED EFFECT ANALGESICS.
HUE031611T2 (en) * 2006-12-21 2017-07-28 H Lundbeck As Modulation of activity of proneurotrophins
ES2533787T3 (en) * 2008-05-22 2015-04-14 H. Lundbeck A/S Modulation of Vps10p domain receptors
US8501178B2 (en) 2008-11-25 2013-08-06 Biogen Idec Ma Inc. Use of DR6 and p75 antagonists to promote survival of cells of the nervous system
TW201034684A (en) * 2009-02-18 2010-10-01 Genentech Inc Method for inhibiting neurodegeneration
WO2011060246A2 (en) * 2009-11-12 2011-05-19 Genentech, Inc. A method of promoting dendritic spine density
US8926978B2 (en) 2011-10-25 2015-01-06 Anaptysbio, Inc. Antibodies directed against nerve growth factor (NGF)
US10849992B1 (en) 2015-04-07 2020-12-01 Alector Llc Methods of screening for sortilin binding antagonists
EA201792221A1 (en) 2015-04-07 2018-08-31 ЭЛЕКТОР ЭлЭлСи ANTIBODIES AGAINST SORTILINE AND METHODS OF THEIR APPLICATION
AU2019246837B2 (en) 2018-07-13 2024-03-21 Alector Llc Anti-Sortilin antibodies and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017878A (en) * 1994-02-07 2000-01-25 Mcgill University Nerve growth factor structural analogs and their uses
WO2001010203A2 (en) * 1999-08-06 2001-02-15 S.I.S.S.A. Scuola Internazionale Superiore Di Studi Avanzati Non-human transgenic animals for the study of neurodegenerative syndromes
WO2002096356A2 (en) * 2001-05-25 2002-12-05 Cornell Research Foundation, Inc. HIGH AFFINITY LIGAND FOR p75 NEUROTROPHIN RECEPTOR

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017878A (en) * 1994-02-07 2000-01-25 Mcgill University Nerve growth factor structural analogs and their uses
WO2001010203A2 (en) * 1999-08-06 2001-02-15 S.I.S.S.A. Scuola Internazionale Superiore Di Studi Avanzati Non-human transgenic animals for the study of neurodegenerative syndromes
WO2002096356A2 (en) * 2001-05-25 2002-12-05 Cornell Research Foundation, Inc. HIGH AFFINITY LIGAND FOR p75 NEUROTROPHIN RECEPTOR

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BEATTIE MICHAEL S ET AL: "ProNGF induces p75-mediated death of oligodendrocytes following spinal cord injury", NEURON, vol. 36, no. 3, October 2002 (2002-10-01), pages 375 - 386, XP002321658, ISSN: 0896-6273 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2003, RAMEE L ET AL: "A novel neurotrophin receptor essential for pro - NGF induced neuronal apoptosis.", XP002321661, Database accession no. PREV200400198170 *
HARRINGTON A W ET AL: "Secreted proNGF is a pathophysiological death-inducing ligand after adult CNS injury", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 101, no. 16, 20 April 2004 (2004-04-20), pages 6226 - 6230, XP002321657, ISSN: 0027-8424 *
NYKJAER ANDERS ET AL: "Sortilin is essential for proNGF-induced neuronal cell death.", NATURE (LONDON), vol. 427, no. 6977, 26 February 2004 (2004-02-26), pages 843 - 848, XP002321660, ISSN: 0028-0836 *
SEDEL FREDERIC ET AL: "Nerve growth factor (NGF) induces motoneuron apoptosis in rat embryonic spinal cord in vitro", EUROPEAN JOURNAL OF NEUROSCIENCE, vol. 11, no. 11, November 1999 (1999-11-01), pages 3904 - 3912, XP002321659, ISSN: 0953-816X *
SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 2003, 2003, 33RD ANNUAL MEETING OF THE SOCIETY OF NEUROSCIENCE; NEW ORLEANS, LA, USA; NOVEMBER 08-12, 2003, pages Abstract No. 334.10 URL - http://sf *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435523B2 (en) 2009-05-04 2013-05-07 Abbott Research B.V. Antibodies against nerve growth factor (NGF) with enhanced in vivo stability

Also Published As

Publication number Publication date
EP1682170A2 (en) 2006-07-26
WO2005044293A2 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
WO2008060813A3 (en) High affinity antibody antagonists of interleukin-13 receptor alpha 1
WO2006034235A3 (en) Substituted quinoline and quinazoline inhibitors of quinone reductase 2
MXPA06011046A (en) Certain triazole-based compounds, compositions, and uses thereof.
WO2008083367A3 (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2008080134A3 (en) 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
WO2005044293A3 (en) Compositions able to prevent neurodegenerative processes and methods of assaying the same
WO2006055752A3 (en) INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1 AND METHODS OF USING THE SAME
EP2484679A3 (en) N3-heteroaryl substituted triazoles and n5-heteroaryl substitued triazoles useful as axl inhibitors
WO2007030680A3 (en) Triazole derivatives useful as axl inhibitors
EP2476679A3 (en) Substituted triazoles useful as AXL inhibitors
TW200716171A (en) Methods for treating and preventing fibrosis
WO2006002361A3 (en) 2-methylpropanamides and their use as pharmaceuticals
WO2006096626A3 (en) Use of opioid antagonists to attenuate endothelial cell proliferation and migration
WO2005023761A3 (en) Cytokine inhibitors
WO2006068826A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
WO2004009062A3 (en) NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau
WO2005000888A3 (en) NOVEL β-ACTIN AND RPS21 PROMOTERS AND USES THEREOF
DE60323091D1 (en) AUTOIMMUNE DISEASES AND NADPH OXIDASE DEFECTS
WO2008049098A3 (en) ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR α1
WO2005105829A3 (en) Caspase-2 inhibitors and their biological applications
WO2002068476A3 (en) Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
WO2005076854A3 (en) Pyrimidinone compounds useful as kinase inhibitors
WO2005000207A3 (en) Pcdgf receptor antibodies and methods of use thereof
WO2007076240A3 (en) Compositions and methods for lipoprotein uptake assays
DE60326263D1 (en) PYRIMIDIN-SULPHONAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004799407

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004799407

Country of ref document: EP